Finger or Toe Endoprosthesis — Cost, Top Hospitals & Success Rates | MyMedicPlus

A finger or toe endoprosthesis is a small prosthetic implant surgically inserted to replace a damaged or destroyed digit joint, restoring function, alignment, and pain-free movement. The word endoprosthesis refers to an implant placed within the body — analogous to hip or knee replacement arthroplasty but on the miniaturised scale of the small joints of the hand and foot.

In the hand, the most commonly replaced joints are the proximal interphalangeal (PIP) joint (the middle knuckle of the finger) and the metacarpophalangeal (MCP) joint (the main knuckle at the base of the finger). In the foot, the metatarsophalangeal (MTP) joint of the great toe is most frequently replaced, particularly in patients with hallux rigidus or inflammatory arthropathy. These small joints bear significant mechanical and dextrous loads during daily activities, and their destruction by arthritis, trauma, or osteonecrosis profoundly impacts quality of life and occupational function.

Three generations of implant technology are in current clinical use — silicone elastomer (Swanson-type), pyrocarbon, and metallic surface replacement — each with distinct mechanical properties and indications. Centres of excellence in Germany, India, South Korea, and Turkey perform digital arthroplasty routinely, providing access to cutting-edge implant systems at substantially reduced cost compared to Western markets.

Finger and toe endoprosthesis is indicated for the following conditions causing irreversible joint destruction:

• Osteoarthritis (primary and post-traumatic): Degenerative joint disease causing cartilage loss, pain, stiffness, and progressive deformity — the most common indication for PIP and MTP joint replacement
• Rheumatoid arthritis: Inflammatory destruction of MCP and PIP joints, frequently associated with ulnar deviation, boutonnière deformity, and swan-neck deformity — silicone implants remain the gold standard for rheumatoid MCP arthroplasty
• Hallux rigidus: End-stage osteoarthritis of the first MTP joint causing rigid, painful great toe with loss of dorsiflexion required for normal gait
• Psoriatic arthritis and crystal arthropathy: Inflammatory joint destruction of small digit joints
• Osteonecrosis of a digit joint: Avascular necrosis of the proximal phalangeal head or metacarpal head
• Post-traumatic arthritis: Joint destruction following intra-articular fracture, ligamentous instability, or inadequately treated fracture-dislocation
• Failed prior fusion (arthrodesis): Patients who underwent joint fusion but suffer significant functional limitation may be candidates for revision arthroplasty

Good candidates for finger or toe joint replacement include patients who:

• Have radiologically confirmed end-stage joint destruction (loss of joint space, subchondral sclerosis, osteophyte formation, or erosive changes)
• Experience significant pain and functional limitation unresponsive to 3–6 months of conservative management (splinting, NSAIDs, corticosteroid injections, physiotherapy)
• Have adequate bone stock at the joint to support implant fixation
• Are able to participate in post-operative hand or foot therapy essential for optimal outcomes
• Have low-to-moderate physical demand on the affected joint (sedentary or light occupational activity)

Contraindications include:

• Active joint infection or osteomyelitis: Absolute contraindication; infection must be fully eradicated before implant surgery
• Severe bone loss or inadequate bone stock: Insufficient bone to anchor the implant; fusion may be a better alternative
• High physical demand (manual workers, athletes): Digital implants are not designed for heavy load-bearing; fusion provides more durable function for high-demand patients
• Severe ligamentous instability: Implants require functional collateral ligaments for stability; gross instability may compromise outcomes
• Nickel or cobalt allergy (for metallic implants): Requires pre-operative allergy testing and alternative implant material selection
• Active uncontrolled inflammatory arthropathy: Disease should be biologically controlled (via DMARDs or biologics) before elective arthroplasty

Digital joint replacement technology has evolved through three generations, offering choices tailored to individual joint anatomy, activity level, and disease characteristics:

Silicone elastomer implants (Swanson design): The longest-established implant, used since the 1960s. A one-piece hinged silicone spacer is inserted through the medullary canals of both bones forming the joint. Functions as a flexible spacer — not a true prosthetic joint. Encapsulation by fibrous tissue over time provides stability. Particularly effective for rheumatoid MCP arthroplasty, where the primary goal is pain relief, deformity correction, and functional positioning rather than normal motion arcs. Long-term survival exceeds 10 years in 70–80% of cases for MCP arthroplasty. Risk of implant fracture (15–25% at 10 years) but many fractured implants remain functional due to fibrous encapsulation.

Pyrocarbon surface replacement arthroplasty: Introduced for PIP joint replacement and increasingly used at the MCP joint. Anatomically shaped condylar components resurface the joint surfaces, preserving the collateral ligaments and joint capsule. Pyrocarbon's mechanical properties (elastic modulus close to cortical bone) minimise stress shielding. Studies report 70–85% implant survival at 10 years for PIP joint pyrocarbon arthroplasty. Preferred for younger, active patients with post-traumatic or primary osteoarthritis who require greater arc of motion. Not recommended in rheumatoid arthritis with poor bone quality.

Metallic total joint replacement (titanium/UHMWPE or cobalt-chrome/polyethylene): Modular metal-on-polyethylene prostheses for PIP, MCP, and MTP joints provide highly durable surfaces. Used in larger joints (MTP) and in patients where bone quality supports secure fixation. Hallux MTP replacement systems (e.g., Cartiva synthetic cartilage implant, ToeFit) have demonstrated non-inferiority to first MTP fusion in randomised trials for hallux rigidus.

Surgical approach: PIP joint replacement is performed through a dorsal (Chamay) or lateral approach under digital or wrist block anaesthesia. The articular surfaces are resected with precision cutting jigs, and the trial components tested for fit, stability, and arc of motion before implanting the definitive prosthesis. MTP arthroplasty is performed through a dorsomedial approach with capsuloligamentous reconstruction.

Digital endoprosthesis provides meaningful functional and symptomatic gains for appropriately selected patients:

• Pain relief: The majority of patients report substantial pain reduction — studies report good or excellent pain outcomes in 75–90% of patients at 5 years
• Motion preservation or restoration: Arthroplasty maintains a functional arc of motion (typically 40–70 degrees for PIP replacement), superior to fusion which eliminates motion entirely
• Deformity correction: Repositioning of deviated or contracted joints restores anatomical alignment and improves hand appearance
• Functional improvement: Patients demonstrate improved pinch strength, grip strength, and hand function scores post-operatively
• Gait restoration (MTP): Great toe joint replacement restores the toe-off phase of walking, reducing compensatory gait adaptations and foot pain
• Quality of life: Validated patient-reported outcome measures (DASH score, VAS pain, FAAM for foot) consistently demonstrate significant improvement in activities of daily living

Digital endoprosthesis is generally well-tolerated, but the following complications should be discussed pre-operatively:

• Implant loosening or subsidence: Occurs in 5–15% of metallic and pyrocarbon implants at 10 years; may require revision to fusion
• Implant fracture (silicone): Silicone spacer fracture rate of 15–25% at 10 years; does not always require revision if the fibrous capsule maintains function
• Instability and dislocation: Lateral instability of the new joint, particularly if collateral ligaments are insufficient; occurs in 3–7% of cases
• Infection (prosthetic joint infection — PJI): Approximately 1–2%; potentially catastrophic requiring implant removal, debridement, and planned two-stage revision or fusion
• Wound healing problems: Dorsal skin over the small joints is thin and tendon-tethered; wound dehiscence occurs in 2–5%
• Stiffness: Inadequate post-operative therapy leading to scar adhesion and limited range of motion; requires intensive hand therapy to prevent
• Nerve injury: Digital nerve bruising or laceration causing numbness or dysaesthesia in the digit
• Revision surgery: Overall revision rates of 10–20% at 10 years, most commonly to arthrodesis (fusion)

Immediately post-surgery (Days 1–5): The operated digit is immobilised in a post-operative splint in a position of function. Elevation of the hand is essential for the first 48–72 hours to minimise swelling. Prescribed analgesics manage pain, which is typically mild to moderate.

Week 1–3: A hand therapist fits a dynamic extension splint (for MCP replacements) or a static protective splint (for PIP replacements). Controlled early active motion exercises begin within 3–5 days for most implant types to prevent tendon adhesion and scar contraction. The therapy protocol is implant-specific and critically important for achieving the motion arc targeted at surgery.

Weeks 4–8: Progressive mobilisation with increasing active and passive range-of-motion exercises. Grip and pinch strengthening begins at 6–8 weeks. Protective splinting is gradually reduced. Light activities of daily living are permitted.

Months 3–6: Maximum functional improvement is typically achieved by 3–6 months. Grip and pinch strength continue to improve for up to 12 months. Occupational therapy assessment to address specific work or leisure demands.

Follow-up schedule:

• Week 2: Suture removal and splinting review
• Week 6: Radiographic check of implant position; therapy review
• Month 3: Functional assessment; range-of-motion measurement
• Month 6 and annually: Long-term implant surveillance with plain radiographs

The cost of finger or toe endoprosthesis varies by joint replaced, implant type, and country. Approximate total costs (surgery, implant, anaesthesia, rehabilitation) include:

• United States: USD 8,000–20,000 per joint (PIP or MCP replacement)
• United Kingdom: GBP 5,000–12,000 (private hospital)
• Germany: EUR 6,000–14,000 — a leading European centre for small joint arthroplasty
• India: USD 2,000–5,000 at JCI/NABH-accredited hospitals — substantial savings with equivalent implant systems
• Turkey: USD 2,500–6,000
• South Korea: USD 3,000–7,000
• Thailand: USD 2,500–6,000

Key cost drivers include: implant type (pyrocarbon and metallic systems are more expensive than silicone), number of joints replaced simultaneously, anaesthesia type, hospital tier, and the inclusion of dedicated hand therapy programmes. Medical tourism packages frequently include implant costs, surgical fees, hospital stay, and post-operative therapy in a single quoted price.

• Arthrodesis (joint fusion): The most durable surgical alternative — eliminates pain with permanent abolition of movement. Preferred for high-demand manual workers, severe bone loss, failed arthroplasty, or infection. DIP joint fusion is often preferred over replacement even in older patients due to reliability
• Corticosteroid joint injections: Provide temporary (3–6 month) pain relief in inflammatory and osteoarthritic joints; appropriate as a bridge to surgery or for patients not yet ready for arthroplasty
• Viscosupplementation (hyaluronic acid injections): Evidence for small digit joints is limited; more established for larger joints
• Splinting and bracing: Offloads the joint and reduces pain during activities; appropriate for mild-to-moderate disease and in patients not yet surgical candidates
• Osteotomy: Realignment of the bone to redistribute joint loading; rarely used in digit joints but may be appropriate for selected peri-articular deformities
• Synovectomy: Surgical removal of inflamed joint lining in early rheumatoid arthritis before cartilage destruction occurs; delays but does not prevent eventual arthroplasty or fusion